Abstract
OBJECTIVE: To investigate the clinical efficacy and safety of levofloxacin (LEV) hydrochloride plus metronidazole (MNZ) in treating pelvic inflammatory disease (PID). METHODS: This retrospective study included 80 PID patients and grouped them based on their treatment regimens: a control group (n=40) treated with LEV hydrochloride injection and a research group (n=40) treated with MNZ plus LEV hydrochloride injection. Clinical efficacy, post-treatment inflammatory indexes, hemorheology (high-/low-shear viscosity [HSV/LSV], plasma viscosity [PV]), symptom resolution time, disease recurrence, as well as pre- and post-treatment pelvic mass diameter, pelvic effusion depth, and quality of life, were compared between the two groups. Adverse reactions during treatment and one-year recurrence were also recorded. RESULTS: Compared with the control group, the research group showed a significantly higher total clinical effective rate and faster clinical symptom resolution (including lower abdominal pain, abnormal leucorrhea, lumbosacral pain, urgent micturition, dysuria, and frequent micturition). Besides, the research group showed smaller pelvic mass diameter and pelvic effusion depth, superior quality of life, lower serum inflammatory markers, and reduced HSV, LSV, and PV levels. The one-year recurrence rate was also significantly lower in the research group. CONCLUSIONS: LEV hydrochloride combined with MNZ is both effective and safe for the treatment of PID, demonstrating notable advantages in promoting inflammation resolution, improving hemorheological parameters, reducing recurrence, and enhancing quality of life.